A new lateral flow test (Cozart RapiScan System) detects MDMA and methamphetamine in oral fluid with high accuracy. Among 370 oral fluid samples, 121 screened positive. Using a 45 ng/mL screening cutoff and 30 ng/mL confirmation cutoff, sensitivity was 96.6%, specificity 96.8%, and accuracy 96.8%. The test also cross-reacts with high levels of amphetamine, causing six false positives. Applying a 50 ng/mL confirmation cutoff improved sensitivity to 98.3%, specificity to 96.9%, and accuracy to 97.3%. Confirmatory testing by gas chromatography-mass spectrometry identified multiple amphetamines.
Combining the sigma1 receptor antagonist CM304 with delta9-tetrahydrocannabinol (THC) enhances pain relief without worsening THC's side effects. In mice, CM304 increased the pain-blocking effect of THC and caused greater body temperature drops when combined. A high dose of CM304 alone reduced movement. In rats, CM304 made THC's pain relief more potent. CM304 did not produce THC-like effects in rats trained to recognize THC, nor did it amplify THC's subjective effects. The findings suggest sigma1 receptor antagonists could be safer adjuncts to cannabinoid-based pain treatments, offering pain relief without increasing adverse effects like sedation or abuse potential.